Dirk Sibbing

Aspirin in Primary Prevention of CVD: A Pragmatic Outline and Advice for Treatment Personalization

Francesca Santilli, Dirk Sibbing, Augusto Lavalle Cobo

Cardiovascular disease (CVD) remains the leading global cause of morbidity and mortality. While low-dose aspirin is well established for secondary prevention, its role in primary prevention is controversial because modest benefits in cardiovascular benefits must be balanced against increased bleeding risk, as …

it, de, ar (code pays fourni par la source)

Dual antiplatelet therapy modulation strategies beyond standard of care: a promising path towards individualized antiplatelet treatment

Dirk Sibbing

This editorial refers to ‘Sex differences in dual antiplatelet therapy de-escalation strategies after percutaneous coronary intervention: a network meta-an

at, de (code pays fourni par la source)

Why low-dose aspirin remains an important antiplatelet in the management of chronic coronary syndromes

Dirk Sibbing, Augusto Lavalle Cobo, Zhongwei Shi, Gerhard Albrecht et autres

Introduction Low-dose aspirin has been the cornerstone of single and dual antiplatelet treatment across the cardiovascular risk continuum. It has a well-established efficacy and safety profile, supported by large-scale, placebo-controlled trials as well as long-standing clinical experience. Low-dose aspirin has the highest …

de, ar, cn, us (code pays fourni par la source)

Pharmaceutical and clinical implications of proton pump inhibitors with dual antiplatelet therapies: a systematic review

Jacob J. Gries, George Triadafilopoulos, Hafeez Ul Hassan Virk, Umair Khalid et autres

Proton pump inhibitors (PPIs) are frequently co-prescribed with dual antiplatelet therapy (DAPT) agents to mitigate the potential of increased gastrointestinal bleeding associated with antiplatelet therapy. Experimental studies have suggested that certain PPIs, such as omeprazole and esomeprazole, may decrease the antiplatelet effects …

us, de (code pays fourni par la source)

International Consensus Statement on Platelet Function and Genetic Testing in Percutaneous Coronary Intervention

Dominick Joseph Angiolillo, Mattía Galli, Dimitrios K. Alexopoulos, Dániel Aradi et autres

us, it, gr, hu, fr, es, de, kr, at, ca, gb, nl, ch (code pays fourni par la source)

Switching Platelet P2Y12 Receptor Inhibiting Therapies

Luis Ortega-Paz, Fabiana Rollini, Francesco Franchi, Dirk Sibbing et autres

us, de (code pays fourni par la source)

Temporary mechanical circulatory support in infarct-related cardiogenic shock: an individual patient data meta-analysis of randomised trials with 6-month follow-up

Holger Thiele, Margriet Bogerd, Matthias Hochadel, Steffen G. Schneider et autres

de, dk, nl, us, cz, gb (code pays fourni par la source)

Clopidogrel Versus Aspirin as Monotherapy Following Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome Receiving a Drug‐Eluting Stent: A Systematic Literature Review and Meta‐Analysis

Dirk Sibbing, Johny Nicolas, Alessandro Spirito, Birgit Vogel et autres

OBJECTIVE: This study aimed to evaluate the comparative effectiveness and safety of clopidogrel versus aspirin as monotherapy following adequate dual antiplatelet therapy (DAPT) in patients with acute coronary syndrome (ACS). METHODS: MEDLINE, Embase, and CENTRAL were searched from database inception to September …

de, us (code pays fourni par la source)

Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary Syndrome

Marco Valgimigli, Antonio Landi, Dominick Joseph Angiolillo, Usman Baber et autres

For almost two decades, 12-month dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS) has been the only class I recommendation on DAPT in American and European guidelines, which has resulted in 12-month durations of DAPT therapy being the most frequently implemented …

ch, us, it, se, jp, ca, fr, de, gb, be (code pays fourni par la source)

The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease

Sungeun Park, Eun‐Seok Shin, Harry K.W. Kim, Dirk Sibbing et autres

East Asian patients have reduced anti-ischemic benefits and increased bleeding risk during antithrombotic therapies compared with Caucasian patients. As potent P2Y 12 receptor inhibitors (e.g., ticagrelor and prasugrel) and direct oral anticoagulants are commonly used in current daily practice, the unique risk-benefit …

us (code pays fourni par la source)

Spoiled for Choice

Dirk Sibbing, Steffen Maßberg, Konstantinos D. Rizas

de (code pays fourni par la source)

Incidence and pattern of urgent revascularization in acute coronary syndromes treated with ticagrelor or prasugrel

Alp Aytekin, Maria Scalamogna, John Joseph Coughlan, Shqipdona Lahu et autres

BACKGROUND: The ISAR-REACT 5 trial compared the efficacy and safety of ticagrelor and prasugrel in patients with ACS managed invasively. The present study sought to investigate the impact of ticagrelor and prasugrel on the incidence and pattern of urgent revascularization in acute …

de, it, us, at (code pays fourni par la source)